Arvee Laboratories (India) Limited is an India-based company engaged in manufacturing of specialized chemicals. The Company's product categories include polymer modifiers, contrast media intermediates and drug intermediates. Its polymer modifiers products include Dimethyl 5-Sodiosulfoisophthalate, 5-Sulfoisophthalic Acid Mono Sodium Salt, 5-Sulfoisophthalic Acid Mono Lithium Salt and 5-Sodiosulfo-Bis-(B-Hydroxyethyl)-Isophthalate. The Company's contrast media intermediates products include 5-Nitroisophthalic acid, Dimethyl 5-Nitroisophthalate, Monomethyl 5-Nitroisophthalate, 5-Hydroxyisophthalic acid, 5-Aminoisophthalic acid, Dimethyl 5-Aminoisophthalate, and 3,5-Diamino Benzoic Acid. Its drug intermediates products include 2-Acetyl Thiophene, Thiophene-2-Carboxaldehyde, 4-Amino Pyridine and 2-Chloro-5-Nitrobenzoic Acid.
ARVEE LABORATORIES I LTD Financial Highlights
- Revenue: ARVEE LABORATORIES I LTD reported revenue of ₹32.19 crore in FY26 vs ₹39.15 crore in FY25. It showed a decrease of 17.78% on a yearly basis.
- Operating Profit: ARVEE LABORATORIES I LTD reported an operating profit of ₹2.43 crore in FY26 vs ₹2.87 crore in FY25. It showed a decrease of 15.33% on a year-on-year basis.
- Net Profit: ARVEE LABORATORIES I LTD reported a net profit of ₹2.53 crore in FY26 vs ₹2.15 crore in FY25. It showed an increase of 17.67% on a yearly basis.
ARVEE LABORATORIES I LTD Quarterly Result Highlights
- ARVEE LABORATORIES I LTD reported revenue of ₹10.95 crore in Mar 2026, compared with ₹9.92 crore in Dec 2025, representing an increase of 10.38% on a quarter-on-quarter (QoQ) basis.
- ARVEE LABORATORIES I LTD reported an operating profit of ₹0.85 crore in Mar 2026, compared with ₹1.39 crore in Dec 2025, representing a decrease of 38.85% on a quarter-on-quarter (QoQ) basis.
- ARVEE LABORATORIES I LTD reported a profit of ₹0.52 crore in Mar 2026, compared with ₹1.83 crore in Dec 2025, reflecting a decrease of 71.58% on a QoQ basis.
- The earnings per share (EPS) of ARVEE LABORATORIES I LTD stood at ₹1.95 during Mar 2026.